Skip to content

XOMA Corporation XOMA Deferred Revenue

Deferred Revenue at other companies

Innoviva, Inc. logo
Innoviva, Inc.INVA
BridgeBio Pharma logo
BridgeBio PharmaBBIO
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's deferred revenue?
XOMA Corporation (XOMA) reported deferred revenue of -$310K in Q1 2026.
How has XOMA Corporation's deferred revenue changed year-over-year?
XOMA Corporation's deferred revenue increased by 2.2% year-over-year, from -$317K to -$310K.
What is the long-term trend for XOMA Corporation's deferred revenue?
Over 4 years (2021 to 2025), XOMA Corporation's deferred revenue has grown at a -5.5% compound annual growth rate (CAGR), from -$1.64M to -$1.31M.